• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Tscan Therapeutics Inc (NQ: TCRX )

    5.040 +0.070 (+1.41%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 170,490
    Open 4.990
    Bid (Size) 4.840 (3)
    Ask (Size) 5.340 (3)
    Prev. Close 4.970
    Today's Range 4.900 - 5.080
    52wk Range 2.430 - 9.690
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    TScan Therapeutics to Participate in Upcoming Investor Conferences
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts
    Via Benzinga

    Performance

    YTD
    -11.73%
    -11.73%
    1 Month
    -11.42%
    -11.42%
    3 Month
    -13.85%
    -13.85%
    6 Month
    -37.08%
    -37.08%
    1 Year
    +92.37%
    +92.37%

    More News

    Read More
    TCRX Stock Earnings: TScan Therapeutics Meets EPS, Misses Revenue for Q2 2024
    Via InvestorPlace
    TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    TScan Therapeutics Announces Updates to its Board of Directors
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    The Analyst Landscape: 7 Takes On TScan Therapeutics
    Via Benzinga
    Key Takeaways From TScan Therapeutics Analyst Ratings
    Via Benzinga
    TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    TCRX Stock Earnings: TScan Therapeutics Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Unveiling 4 Analyst Insights On TScan Therapeutics
    Via Benzinga
    TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    TScan Therapeutics Announces Closing of Upsized Public Offering
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With
    Via InvestorPlace
    TCRX Stock Earnings: TScan Therapeutics Beats EPS, Beats Revenue for Q4 2023
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.